Focused On-demand Library for Secreted Ly-6/uPAR-related protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P55000

UPID:

SLUR1_HUMAN

Alternative names:

ARS component B; ARS(component B)-81/S; Anti-neoplastic urinary protein

Alternative UPACC:

P55000; Q53YJ6; Q6PUA6; Q92483

Background:

Secreted Ly-6/uPAR-related protein 1, also known as ARS component B, plays a pivotal role in skin differentiation and integrity. It exhibits antitumor activity and is a marker of late skin differentiation. Its functions include down-regulation of keratinocyte proliferation, modulation of nicotinic acetylcholine receptors, and involvement in T cell Ca(2+) signaling and corneal immunomodulation. It potentially acts as a scavenger receptor for PLAU, influencing cell migration and proliferation.

Therapeutic significance:

Secreted Ly-6/uPAR-related protein 1's association with Mal de Meleda, a rare skin disorder, underscores its clinical relevance. Understanding its role could pave the way for innovative treatments for skin diseases and cancer, highlighting its therapeutic potential.